Bristol Myers Squibb (CELG-RI) EBT Margin (2009 - 2026)
Bristol Myers Squibb (CELG-RI) reported EBT Margin of 28.2% for Q1 2026, up 168.0% year-over-year from 10.52% in Q1 2025, and up 139.84% quarter-over-quarter from 11.76% in Q4 2025.
Bristol Myers Squibb (CELG-RI) EBT Margin (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 18 years of EBT Margin data on file, last reported at 28.2% in Q1 2026.
- EBT Margin for Q1 2026 came in at 28.2%, up 168.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 19.79% (up 697.0% YoY), and the FY2025 annual result was 19.36%, up 3670.0% from the prior year.
- EBT Margin rose to 28.2% in Q1 2026 per CELG-RI's latest filing, from 11.76% in the prior quarter.
- Over five years, EBT Margin peaked at 28.2% in Q1 2026 and troughed at 97.06% in Q1 2024.
- A 5-year average of 10.44% and a median of 16.3% in 2022 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2024 and 2025: EBT Margin sank 12149 bps in 2024, then soared 12358 bps in 2025.
- A 5-year view of EBT Margin shows it stood at 16.3% in 2022, then slipped by 11 bps to 14.59% in 2023, then slumped by 90 bps to 1.42% in 2024, then soared by 729 bps to 11.76% in 2025, then soared by 140 bps to 28.2% in 2026.
- Business Quant data shows CELG-RI's EBT Margin at 28.2% in Q1 2026, 11.76% in Q4 2025, and 25.48% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 28.10% |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 44.70% |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 24.89% |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 6.93% |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -21.49% |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 24.18% |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 37.07% |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 135.53% |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 28.20% |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | 28.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.20% |
| Dec 31, 2025 | 11.76% |
| Sep 30, 2025 | 25.48% |
| Jun 30, 2025 | 14.45% |
| Mar 31, 2025 | 26.52% |
| Dec 31, 2024 | 1.42% |
| Sep 30, 2024 | 14.09% |
| Jun 30, 2024 | 10.54% |
| Mar 31, 2024 | -97.06% |
| Dec 31, 2023 | 14.59% |
| Sep 30, 2023 | 19.49% |
| Jun 30, 2023 | 16.56% |
| Mar 31, 2023 | 24.43% |
| Dec 31, 2022 | 16.30% |
| Sep 30, 2022 | 19.69% |
| Jun 30, 2022 | 16.47% |
| Mar 31, 2022 | 14.48% |
| Dec 31, 2021 | 15.50% |
| Sep 30, 2021 | 18.56% |
| Jun 30, 2021 | 13.27% |